| Literature DB >> 24398933 |
Thavarak Ouk1, Sophie Gautier1, Maud Pétrault1, David Montaigne2, Xavier Maréchal3, Isabelle Masse1, Jean-Christophe Devedjian4, Dominique Deplanque1, Michèle Bastide1, Rémi Nevière3, Patrick Duriez1, Bart Staels5, Florence Pasquier6, Didier Leys7, Régis Bordet1.
Abstract
In stroke, there is an imperative need to develop disease-modifying drugs able to (1) induce neuroprotection and vasculoprotection, (2) modulate recovery and brain plasticity, and (3) limit the short-term motor and cognitive consequences. We hypothesized that fenofibrate, a peroxisome proliferator-activated receptor-α (PPAR-α) agonist, could exert a beneficial effect on immediate and short-term poststroke consequences related to its pleiotropic mechanisms. Rats or mice were subjected to focal ischemia to determine the effects of acute treatment by fenofibrate on (i) motor and memory impairment, (2) both cerebral and vascular compartments, (3) inflammation, (4) neurogenesis, and (5) amyloid cascade. We show that fenofibrate administration results in both neuronal and vascular protection and prevents the short-term motor and cognitive poststroke consequences by interaction with several mechanisms. Modulation of PPAR-α generates beneficial effects in the immediate poststroke consequences by mechanisms involving the interactions between polynuclear neutrophils and the vessel wall, and microglial activation. Fenofibrate modulates mechanisms involved in neurorepair and amyloid cascade. Our results suggest that PPAR-α agonists could check the key points of a potential disease-modifying effect in stroke.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24398933 PMCID: PMC3948136 DOI: 10.1038/jcbfm.2013.233
Source DB: PubMed Journal: J Cereb Blood Flow Metab ISSN: 0271-678X Impact factor: 6.200